Effect of adjuvant endocrine therapy on hormonal levels in premenopausal women with breast cancer: The ProBONE II study

Breast Cancer Research and Treatment

Volumn 144, Issue 2, 2014, Pages 343-351

  Hadji, Peyman ^a   Kauka, Annette ^a   Ziller, May ^a   Birkholz, Katrin ^b   Baier, Monika ^b   Muth, Mathias ^b   Kann, Peter ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b NOVARTIS PHARMA GMBH   (Germany)

Author keywords

Adjuvant; Endocrine therapy; Hormone receptor positive breast cancer; Premenopausal; Serum hormones; Zoledronic acid

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; ESTRADIOL; FLUOROURACIL; FOLLITROPIN; GONADORELIN DERIVATIVE; GOSERELIN; INHIBIN A; INHIBIN B; MUELLERIAN INHIBITING FACTOR; PARATHYROID HORMONE; PLACEBO; RALOXIFENE; SEX HORMONE BINDING GLOBULIN; TAMOXIFEN; TAXANE DERIVATIVE; TESTOSTERONE; VITAMIN D; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; HORMONE; IMIDAZOLE DERIVATIVE; TUMOR MARKER;

ADJUVANT THERAPY; ADULT; ARTHRALGIA; ARTICLE; BACKACHE; BONE PAIN; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CHILL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; FEMALE; FLU LIKE SYNDROME; FOLLITROPIN BLOOD LEVEL; FOLLOW UP; HEADACHE; HORMONE BLOOD LEVEL; HORMONE RECEPTOR POSITIVE BREAST CANCER; HOT FLUSH; HUMAN; LYMPHEDEMA; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; NAUSEA; PARATHYROID HORMONE BLOOD LEVEL; PARESTHESIA; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; VITAMIN BLOOD LEVEL; ADJUVANT CHEMOTHERAPY; BLOOD; BREAST NEOPLASMS; DRUG EFFECTS; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROSPECTIVE STUDY; YOUNG ADULT;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FEMALE; GOSERELIN; HORMONES; HUMANS; IMIDAZOLES; MIDDLE AGED; PREMENOPAUSE; PROSPECTIVE STUDIES; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84896542372     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-2860-7     Document Type: Article

References (25)

1. Palmieri C, Patten DK, Januszewski A, Zucchini G, Howell SJ (2013) Breast cancer: current and future endocrine therapies. Mol Cell Endocrinol. doi:10.1016/j.mce.2013.08.001
2. Bines J, Oleske DM, Cobleigh MA (1996) Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14:1718-1729 (Pubitemid 26134232)
3. Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu-Zahra H, Findlay B, Warr D, Bowman D, Myles J, Arnold A, Vandenberg T, MacKenzie R, Robert J, Ottaway J, Burnell M, Williams CK, Tu D (1998) Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16:2651-2658 (Pubitemid 28363028)
4. Shapiro CL, Manola J, Leboff M (2001) Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 19:3306-3311 (Pubitemid 32642182)
5. Petrek JA, Naughton MJ, Case LD, Paskett ED, Naftalis EZ, Singletary SE, Sukumvanich P (2006) Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 24:1045-1051 (Pubitemid 46638800)
6. Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I (1997) Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 15:1341-1347 (Pubitemid 27167365)
7. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kassmann H, Piswanger-Solkner JC, Seifert M, Ploner F, Menzel C, Dubsky P, Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Wohlmuth P, Mittlbock M, Jakesz R (2008) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 9:840-849
8. Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, Fan M, Jun S (2008) Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26:4875-4882
9. Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P, von MG, Sleeboom HP, Forbes J, Barrios C, Frassoldati A, Campbell I, Paija O, Martin N, Modi A, Bundred N (2013) Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol 24:398-405
10. Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, Gil M, Houston SJ, Grieve RJ, Barrett-Lee PJ, Ritchie D, Pugh J, Gaunt C, Rea U, Peterson J, Davies C, Hiley V, Gregory W, Bell R (2011) Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 365:1396-1405
11. Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, Jakesz R, Seifert M, Hubalek M, Pristauz G, Bauernhofer T, Eidtmann H, Eiermann W, Steger G, Kwasny W, Dubsky P, Hochreiner G, Forsthuber EP, Fesl C, Greil R (2011) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 12:631-641
12. Hadjidakis DJ, Androulakis II (2006) Bone remodeling. Ann NY Acad Sci 1092:385-396 (Pubitemid 47092355)
13. Nicks KM, Fowler TW, Akel NS, Perrien DS, Suva LJ, Gaddy D (2010) Bone turnover across the menopause transition: the role of gonadal inhibins. Ann NY Acad Sci 1192:153-160
14. Pacifici R, Brown C, Puscheck E, Friedrich E, Slatopolsky E, Maggio D, McCracken R, Avioli LV (1991) Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc Natl Acad Sci USA 88:5134-5138 (Pubitemid 21914698)
15. Dowsett M, Doody D, Miall S, Howes A, English J, Coombes RC (1999) Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer. Breast Cancer Res Treat 56:25-34 (Pubitemid 29435812)
16. Stein RC, Dowsett M, Hedley A, Gazet JC, Ford HT, Coombes RC (1990) The clinical and endocrine effects of 4-hydroxy-androstenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer. Br J Cancer 62:679-683 (Pubitemid 20340591)
17. Forward DP, Cheung KL, Jackson L, Robertson JF (2004) Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer 90:590-594 (Pubitemid 38297195)
18. Madeira M, Mattar A, Logullo AF, Soares FA, Gebrim LH (2013) Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness-a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer. BMC Cancer 13:425
19. Fogelmann I (2001) Assessment of BMD in pre/postmenopausal women treated with Zoladex versus CMF. Results from the ZEBRA study. St Gallen Proceedings
20. Rossi E, Morabito A, De ME, Di RF, Esposito G, Gravina A, Labonia V, Landi G, Nuzzo F, Pacilio C, Piccirillo MC, D'Aiuto G, D'Aiuto M, Rinaldo M, Botti G, Gallo C, Perrone F, de Matteis A (2008) Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancer. J Clin Oncol 26:264-270
21. Rossi E, Morabito A, Di RF, Esposito G, Gravina A, Labonia V, Landi G, Nuzzo F, Pacilio C, De ME, Di MM, Piccirillo MC, De FG, D'Aiuto G, Botti G, Chiodini P, Gallo C, Perrone F, de Matteis A (2009) Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial. J Clin Oncol 27:3192-3197
22. Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Poestlberger S, Dubsky PC, Jakesz R, Singer CF, Eidtmann H, Greil R (2011) Overall survival with adjuvant zoledronic acid in patients with premenopausal breast cancer with complete endocrine blockade: Long-term results from ABCSG-12. J Clin Oncol 29(suppl):50s
23. Kim JE, Ahn JH, Jung KH, Kim SB, Kim HJ, Lee KS, Ro JS, Park YH, Ahn JS, Im YH, Im SA, Lee MH, Kim SY (2011) Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01). Breast Cancer Res Treat 125:99-106
24. Hadji P, Coleman R, Gnant M, Green J (2012) The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis. Ann Oncol 23:2782-2790
25. Smith IE, Dowsett M, Yap YS, Walsh G, Lonning PE, Santen RJ, Hayes D (2006) Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol 24:2444-2447 (Pubitemid 46630620)